bardoxolone Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease […]
bardoxolone
bardoxolone Reata Pharmaceuticals, Inc. Submits NDA for Company’s Lead Program: Bardoxolone in Alport Syndrome PLANO, Texas, March 01, 2021 (GLOBE NEWSWIRE) — Reata […]